HRP20170393T1 - Inhibitori c-fms kinaze - Google Patents

Inhibitori c-fms kinaze Download PDF

Info

Publication number
HRP20170393T1
HRP20170393T1 HRP20170393TT HRP20170393T HRP20170393T1 HR P20170393 T1 HRP20170393 T1 HR P20170393T1 HR P20170393T T HRP20170393T T HR P20170393TT HR P20170393 T HRP20170393 T HR P20170393T HR P20170393 T1 HRP20170393 T1 HR P20170393T1
Authority
HR
Croatia
Prior art keywords
image
alkyl
pharmaceutically acceptable
compound according
tautomers
Prior art date
Application number
HRP20170393TT
Other languages
English (en)
Inventor
Carl R. Illig
Jinsheng Chen
Sanath K. Meegalla
Mark J. Wall
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20170393T1 publication Critical patent/HRP20170393T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Claims (10)

1. Spoj formule I: [image] ili solvat, hidrat, tautomer ili njegova farmaceutski prihvatljiva sol, naznačeno time da: W je [image] ili [image] pri čemu svaka R4 je nezavisno H, F, Cl, Br, I, OH, OCH3, OCH2CH3, SC(1-4)alkil, SOC(1-4)alkil, SO2C(1-4)alkil, -C(1-3)alkil, CO2Rd, CONReRf, C≡CRg, ili CN; gdje Rd je H, ili -C(1-3)alkil; Re je H, ili -C(1-3)alkil; Rf je H, ili -C(1-3)alkil; i Rg je H, -CH2OH, ili -CH2CH2OH; R2 je cikloalkil, spiro-supstituirani cikloalkenil, tiofenil, dihidrosulfonopiranil, fenil, furanil, tetrahidropiridil, ili dihidropiranil, od kojih svaki može biti nezavisno supstituiran sa jednim ili dva od svaka sljedeća: kloro, fluoro, hidroksi, C(1-3)alkila, i C(1-4)alkila; Z je H, F, Cl, ili CH3; J je CH, ili N; X je [image] [image] ili [image] pri čemu Rw je H, -C(1-4)alkil, -CO2C(1-4)alkil, -CONH2, -CONHC(1-4)alkil, -CON(C(1-4)alkil)2, ili -COC(1-4)alkil.
2. Spoj prema patentnom zahtjevu 1, naznačen time da: W je [image] ili [image] R2 je [image] [image] ili [image] Z je H; X je [image] [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
3. Spoj prema patentnom zahtjevu 2, naznačen time da: W je [image] [image] [image] ili [image] R2 je [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
4. Spoj prema patentnom zahtjevu 3, naznačen time da: W je [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
5. Spoj prema patentnom zahtjevu 4, naznačen time da: W je [image] R2 je [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
6. Spoj prema patentnom zahtjevu 1, Formule Ia: [image] naznačen time da: R2je [image] ili [image] J je CH, ili N; i X je [image] [image] ili [image] pri čemu Rw je H, -C(1-4)alkil, -CO2C(1-4)alkil, -CONH2, -CONHC(1-4)alkil, -CON(C(1-4)alkil)2, ili -COC(14)alkil; ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
7. Spoj prema patentnom zahtjevu 6, naznačen time da X je [image] [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
8. Spoj prema patentnom zahtjevu 1 naznačen time da je formule [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
9. Farmaceutski pripravak, naznačen time da obuhvaća spoj iz patentnog zahtjeva 1 i farmaceutski prihvatljiv nosač.
10. Najmanje jedan spoj prema patentnom zahtjevu 1, naznačen time da je za upotrebu u postupku liječenja bolesti izabrane iz grupe koja se sastoji od osteoporoze, Pagetove bolesti, reumatskog artritisa i drugih oblika inflamatornog artritisa, osteoartritisa, protetičkih nedostataka, osteolitičkog sarkoma, mijeloma, i metastaze tumora na kosti.
HRP20170393TT 2007-10-17 2017-03-09 Inhibitori c-fms kinaze HRP20170393T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98062307P 2007-10-17 2007-10-17
EP08839490.3A EP2215079B1 (en) 2007-10-17 2008-10-16 Inhibitors of c-fms kinase
PCT/US2008/080081 WO2009052237A1 (en) 2007-10-17 2008-10-16 Inhibitors of c-fms kinase

Publications (1)

Publication Number Publication Date
HRP20170393T1 true HRP20170393T1 (hr) 2017-05-05

Family

ID=40352814

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20211593TT HRP20211593T1 (hr) 2007-10-17 2008-10-16 Inhibitori kinaze c-fms
HRP20170393TT HRP20170393T1 (hr) 2007-10-17 2017-03-09 Inhibitori c-fms kinaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20211593TT HRP20211593T1 (hr) 2007-10-17 2008-10-16 Inhibitori kinaze c-fms

Country Status (36)

Country Link
US (1) US8497376B2 (hr)
EP (2) EP3208269B1 (hr)
JP (1) JP5475672B2 (hr)
KR (1) KR101559326B1 (hr)
CN (1) CN101889009B (hr)
AR (1) AR068892A1 (hr)
AU (1) AU2008312540B2 (hr)
BR (1) BRPI0817843B8 (hr)
CA (1) CA2702898C (hr)
CL (1) CL2008003068A1 (hr)
CO (1) CO6270363A2 (hr)
CR (1) CR11433A (hr)
CY (2) CY1118717T1 (hr)
DK (2) DK2215079T3 (hr)
EA (1) EA018936B1 (hr)
ES (2) ES2614754T3 (hr)
HR (2) HRP20211593T1 (hr)
HU (2) HUE031555T2 (hr)
IL (1) IL205043A (hr)
JO (1) JO3240B1 (hr)
LT (2) LT3208269T (hr)
MX (1) MX2010004263A (hr)
MY (1) MY153951A (hr)
NI (1) NI201000059A (hr)
NZ (1) NZ584574A (hr)
PA (1) PA8799701A1 (hr)
PE (1) PE20090972A1 (hr)
PL (2) PL3208269T3 (hr)
PT (2) PT2215079T (hr)
RS (2) RS62569B1 (hr)
SI (2) SI3208269T1 (hr)
TW (1) TWI440637B (hr)
UA (1) UA99311C2 (hr)
UY (1) UY31397A1 (hr)
WO (1) WO2009052237A1 (hr)
ZA (1) ZA201003429B (hr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
PL2021335T3 (pl) 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2650057C (en) 2006-04-20 2014-07-29 Janssen Pharmaceutica N.V. Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase
TWI619713B (zh) * 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
AU2013299922B2 (en) * 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) * 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EA201590381A1 (ru) 2012-08-16 2015-07-30 Янссен Фармацевтика Нв Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX2015012344A (es) 2013-03-15 2016-06-02 Janssen Pharmaceutica Nv 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.
MX365315B (es) * 2013-03-15 2019-05-29 Janssen Pharmaceutica Nv Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
JP6239113B2 (ja) * 2013-08-16 2017-11-29 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル拮抗薬としての置換イミダゾール
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
KR102100539B1 (ko) * 2013-12-19 2020-04-13 아처 다니엘 미드랜드 캄파니 푸란-2,5-디메탄올 및 (테트라하이드로푸란-2,5-디일)디메탄올의 모노- 및 디알킬 에테르 및 그 양친매성 유도체
JP6537338B2 (ja) * 2015-04-24 2019-07-03 日東電工株式会社 核酸固相合成用リンカー及び担体
KR20180107142A (ko) * 2016-02-11 2018-10-01 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-옥시이미다졸릴-카르복스아미드
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
TW201811326A (zh) 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
EP3589324A1 (en) * 2017-03-03 2020-01-08 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
WO2020222109A1 (en) 2019-05-02 2020-11-05 Janssen Biotech, Inc. Csf-1/csf-1r gene set
CN110575450B (zh) * 2019-09-17 2023-03-31 遵义医科大学珠海校区 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) * 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
US5190541A (en) * 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1996011932A1 (en) 1994-10-14 1996-04-25 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
DE29624503U1 (de) 1995-04-19 2004-09-16 Boston Scientific Scimed, Inc. Arzneimittel-freisetzender beschichteter Stent
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HU221227B1 (en) * 1995-12-08 2002-08-28 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their use
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) * 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
EP0923557A4 (en) 1996-08-09 1999-12-08 Merck & Co Inc STEREOSELECTIVE DEOXY GENERATION REACTION
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
CN1095845C (zh) 1996-12-20 2002-12-11 "塔比法尔"有限责任公司 制取冻干的1β,10β－环氧－13－二甲基氨基－愈创－3(4)－烯－6,12－内酯盐酸盐的方法和装置
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
WO1999045712A1 (en) 1998-03-05 1999-09-10 Formula One Administration Limited Data communication system
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2341690C (en) 1998-08-27 2007-04-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
SK286072B6 (sk) 1998-12-23 2008-02-05 Janssen Pharmaceutica N. V. 1,2-anelované chinolínové deriváty, spôsob ich prípravy, medziprodukty, farmaceutický prostriedok aich použitie
DE1140938T1 (de) 1999-01-11 2003-01-09 Princeton University Princeton Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
ID30460A (id) * 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1242385B1 (en) 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) * 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) * 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
IL162203A0 (en) 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
US7122550B2 (en) 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4741948B2 (ja) 2002-08-14 2011-08-10 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターおよびそれらの使用
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004022525A1 (en) 2002-09-05 2004-03-18 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
WO2004030635A2 (en) * 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
WO2004043389A2 (en) 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
WO2004089918A1 (ja) * 2003-04-09 2004-10-21 Japan Tobacco Inc. 複素芳香５員環化合物及びその医薬用途
US7790724B2 (en) * 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
EP1631560A2 (en) 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
NZ545032A (en) 2003-07-28 2009-02-28 Smithkline Beecham Corp Cycloalkylidene compounds as modulators of estrogen receptor
AU2004283162B2 (en) 2003-10-23 2011-12-15 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
WO2005073225A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
MX2007004784A (es) * 2004-10-22 2007-09-11 Johnson & Johnson Inhibidores de la c-fms cinasa.
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
ATE437864T1 (de) * 2004-10-22 2009-08-15 Janssen Pharmaceutica Nv Aromatische amide als hemmer der c-fms-kinase
US7662837B2 (en) * 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
BRPI0617489A2 (pt) * 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase
PL2021335T3 (pl) * 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
US8697716B2 (en) * 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2650057C (en) * 2006-04-20 2014-07-29 Janssen Pharmaceutica N.V. Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase
US8674100B2 (en) * 2006-04-20 2014-03-18 Janssen Pharmaceutica, N.V. Inhibitors of C-FMS kinase

Also Published As

Publication number Publication date
LT3208269T (lt) 2021-11-10
EA201070480A1 (ru) 2010-10-29
BRPI0817843B1 (pt) 2019-01-02
EP3208269A1 (en) 2017-08-23
CN101889009A (zh) 2010-11-17
JO3240B1 (ar) 2018-03-08
RS62569B1 (sr) 2021-12-31
CY1118717T1 (el) 2017-07-12
HRP20211593T1 (hr) 2022-03-18
IL205043A (en) 2015-07-30
CA2702898C (en) 2016-10-11
KR20100069711A (ko) 2010-06-24
IL205043A0 (en) 2010-11-30
MY153951A (en) 2015-04-15
EP3208269B1 (en) 2021-09-15
ES2614754T3 (es) 2017-06-01
TWI440637B (zh) 2014-06-11
UA99311C2 (en) 2012-08-10
PT2215079T (pt) 2017-03-23
EP2215079A1 (en) 2010-08-11
BRPI0817843B8 (pt) 2021-05-25
EA018936B1 (ru) 2013-11-29
NZ584574A (en) 2011-12-22
SI2215079T1 (sl) 2017-05-31
CA2702898A1 (en) 2009-04-23
ES2905118T3 (es) 2022-04-07
CR11433A (es) 2011-01-14
EP2215079B1 (en) 2016-12-14
CN101889009B (zh) 2014-10-29
RS55860B1 (sr) 2017-08-31
US8497376B2 (en) 2013-07-30
DK3208269T3 (da) 2021-10-11
SI3208269T1 (sl) 2021-11-30
CO6270363A2 (es) 2011-04-20
HUE056173T2 (hu) 2022-01-28
NI201000059A (es) 2010-09-13
CL2008003068A1 (es) 2009-03-06
HUE031555T2 (en) 2017-07-28
MX2010004263A (es) 2010-05-03
AU2008312540A1 (en) 2009-04-23
KR101559326B1 (ko) 2015-10-12
JP2011501752A (ja) 2011-01-13
ZA201003429B (en) 2011-08-31
AU2008312540B2 (en) 2014-03-27
PL3208269T3 (pl) 2022-01-10
US20090105296A1 (en) 2009-04-23
DK2215079T3 (en) 2017-02-13
PA8799701A1 (es) 2009-05-15
UY31397A1 (es) 2009-04-30
PE20090972A1 (es) 2009-07-13
PL2215079T3 (pl) 2017-06-30
PT3208269T (pt) 2021-12-09
BRPI0817843A2 (pt) 2015-04-07
TW200932738A (en) 2009-08-01
JP5475672B2 (ja) 2014-04-16
LT2215079T (lt) 2017-01-25
CY1124721T1 (el) 2022-07-22
AR068892A1 (es) 2009-12-16
WO2009052237A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
HRP20170393T1 (hr) Inhibitori c-fms kinaze
HRP20191027T1 (hr) Derivati imidazopiridina kao inhibitori tiposinskih receptora kinaza
ES2528451T3 (es) Inhibidores de esfingosina cinasa
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
MEP51408A (hr) Odobreni antagonisti cgrp, postupci za njihovo dobijanje i njihova primjena kao farmaceutskih kompozicija
PH12015502114B1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20160002T1 (hr) Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
AR060608A1 (es) Inhibidores de la quinasa c- fms
RU2011147726A (ru) Диариловые эфиры
AR060612A1 (es) Inhibidores de la quinasa c- fms
WO2009136995A3 (en) 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
HRP20170499T1 (hr) Derivati tiazola
NZ708801A (en) Aryl and heteroaryl fused lactams
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
MX2013002651A (es) Derivados de benzoxaborol para tratar infecciones bacterianas.
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
HRP20110841T1 (hr) Korisni monobaktamski antibiotici
RS53385B (en) DERIVATIVES OF HINAZOLIN-4 (3H) -ONE USED AS PI3 KINASE INHIBITOR
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
WO2010135429A3 (en) Compositions for modulating a kinase cascade and mehtods of use thereof
EA201590023A1 (ru) Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
HRP20110938T1 (hr) Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora